Javascript must be enabled to continue!
Features of Bone Mineral Density, Calcium-Phosphorus Metabolism and Bone Remodeling in Patients with Systemic Lupus Erythematosus
View through CrossRef
Introduction. Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations associated with multiple autoantibodies formation and deposition of immune complexes, and other immune processes. Despite significant advances in treatment, the disease remains disabling, in particular, due to increased bone fragility and low-energy fractures. The study of bone remodeling in patients with SLE should help to improve the therapy and quality of their treatment.
The aim of the study. To investigate the features of bone mineral density, calcium-phosphorus metabolism and bone remodeling in patients with systemic lupus erythematosus.
Materials and methods. The study involved 123 women with SLE aged 21-51 years. The comparison group (CG) consisted of 25 women without SLE in premenopausal status of the appropriate age. The control group included 25 practically healthy women.
In order to study bone mineral density (BMD), dual-energy X-ray densitometry (DXA) of the lumbar spine was performed using a dual-energy X-ray absorptiometer. For the study of calcium-phosphorus metabolism (CPM), total calcium (Ca), ionized Ca, phosphorus (P) in blood and Ca, P, creatinine in daily urine, as well as parathyroid hormone (PTH) and 25-hydroxyvitamin D in serum were determined. Markers of bone remodeling (osteocalcin, procollagen type 1 amino-terminal propeptide (P1NP) and isomerized C-terminal telopeptide (β-crosslaps) in serum were measured.
To achieve the stated goal, the first step included the determination of bone damage prevalence in patients with the diagnosed SLE; the second step was directed towards the characterization the particular bone condition in patients with SLE based on the results of BMD, CPM indices and markers of bone remodeling assessment.
Results and discussion. According to the results of DXA of the lumbar spine, 88 (71.54 %) women of the SG and only 8 (32.00 %) women of the CG had a decrease in BMD (p < 0.001). According to the mean values, the studied CPM indices of the SG patients, CG and control group wemen exposed no significant differences. Similarly, no significant differences were detected in the mean values of urinary phosphorus and in between blood PTH values in SG, CG, and control. The level of 25-hydroxyvitamin D was significantly lower in SG (15.14 ± 0.80 ng/ml) than in CG (19.62 ± 0.46 ng/ml) and control (22.38 ± 1.34 ng/ml) p < 0.05. The mean value of osteocalcin in woman with SLE was significantly lower than in CG and control (11.81 ± 0.49 ng/ml versus 18.61 ± 0.75 ng/ml and 19.28 ± 1.88, p < 0.001). No significant difference were detected in between the mean values of P1NP in SG, CG and control. The mean values of β-cross laps were significantly higher in patients with SLE (0.51 ± 0.02 ng/ml) compared to GC (0.26 ± 0.02 ng/ml) and control (0.28 ± 0.02 ng/ml), p < 0.001.
Conclusions. Bone mineral density, calcium-phosphorus metabolism and bone remodeling in patients with systemic lupus erythematosus have peculiarities as follows: a significant decrease in bone mass in 71.54 % of patients, namely 18, 70 % - grade I osteopenia, 21.14 % - grade II osteopenia, 14.63 % - grade III osteopenia; 17.07 % - osteoporosis, increased calcium excretion, vitamin D deficiency, decreased osteoblastic and enhansed osteoclastic functions.
Danylo Halytskyi Lviv National Medical University
Title: Features of Bone Mineral Density, Calcium-Phosphorus Metabolism and Bone Remodeling in Patients with Systemic Lupus Erythematosus
Description:
Introduction.
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations associated with multiple autoantibodies formation and deposition of immune complexes, and other immune processes.
Despite significant advances in treatment, the disease remains disabling, in particular, due to increased bone fragility and low-energy fractures.
The study of bone remodeling in patients with SLE should help to improve the therapy and quality of their treatment.
The aim of the study.
To investigate the features of bone mineral density, calcium-phosphorus metabolism and bone remodeling in patients with systemic lupus erythematosus.
Materials and methods.
The study involved 123 women with SLE aged 21-51 years.
The comparison group (CG) consisted of 25 women without SLE in premenopausal status of the appropriate age.
The control group included 25 practically healthy women.
In order to study bone mineral density (BMD), dual-energy X-ray densitometry (DXA) of the lumbar spine was performed using a dual-energy X-ray absorptiometer.
For the study of calcium-phosphorus metabolism (CPM), total calcium (Ca), ionized Ca, phosphorus (P) in blood and Ca, P, creatinine in daily urine, as well as parathyroid hormone (PTH) and 25-hydroxyvitamin D in serum were determined.
Markers of bone remodeling (osteocalcin, procollagen type 1 amino-terminal propeptide (P1NP) and isomerized C-terminal telopeptide (β-crosslaps) in serum were measured.
To achieve the stated goal, the first step included the determination of bone damage prevalence in patients with the diagnosed SLE; the second step was directed towards the characterization the particular bone condition in patients with SLE based on the results of BMD, CPM indices and markers of bone remodeling assessment.
Results and discussion.
According to the results of DXA of the lumbar spine, 88 (71.
54 %) women of the SG and only 8 (32.
00 %) women of the CG had a decrease in BMD (p < 0.
001).
According to the mean values, the studied CPM indices of the SG patients, CG and control group wemen exposed no significant differences.
Similarly, no significant differences were detected in the mean values of urinary phosphorus and in between blood PTH values in SG, CG, and control.
The level of 25-hydroxyvitamin D was significantly lower in SG (15.
14 ± 0.
80 ng/ml) than in CG (19.
62 ± 0.
46 ng/ml) and control (22.
38 ± 1.
34 ng/ml) p < 0.
05.
The mean value of osteocalcin in woman with SLE was significantly lower than in CG and control (11.
81 ± 0.
49 ng/ml versus 18.
61 ± 0.
75 ng/ml and 19.
28 ± 1.
88, p < 0.
001).
No significant difference were detected in between the mean values of P1NP in SG, CG and control.
The mean values of β-cross laps were significantly higher in patients with SLE (0.
51 ± 0.
02 ng/ml) compared to GC (0.
26 ± 0.
02 ng/ml) and control (0.
28 ± 0.
02 ng/ml), p < 0.
001.
Conclusions.
Bone mineral density, calcium-phosphorus metabolism and bone remodeling in patients with systemic lupus erythematosus have peculiarities as follows: a significant decrease in bone mass in 71.
54 % of patients, namely 18, 70 % - grade I osteopenia, 21.
14 % - grade II osteopenia, 14.
63 % - grade III osteopenia; 17.
07 % - osteoporosis, increased calcium excretion, vitamin D deficiency, decreased osteoblastic and enhansed osteoclastic functions.
Related Results
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus erythematosus) and non-s...
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
Crucial Role of Foxp3 Gene Expression and Mutation in Systemic Lupus Erythematosus, Inferred from Computational and Experimental Approaches
The impaired suppressive function of regulatory T cells is well-understood in systemic lupus erythematosus. This is likely due to changes in Foxp3 expression that are crucial for r...
British Food Journal Volume 45 Issue 9 1943
British Food Journal Volume 45 Issue 9 1943
I now pass on to an aspect of calcium metabolism which is more topical, but probably more controversial. I refer to the incidence of calcium deficiency. By what means can we determ...
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
BRIEF REVIEW ABOUT NEUROLOGICAL, HEMATOLOGICAL, GASTROINTESTINAL, CARDIOVASCULAR AND PULMONAR MANIFESTATIONS OF SYSTEMIC ERYTHEMATOSUS LUPUS
Systemic Lupus Erythematosus is an autoimmune multisystem pathology, characterized by being more prevalent in women, especially African women. One of the most frequent pathologies ...
MO215DEPRESSIVE DISORDER IN LUPIC PATIENTS WITH LUPUS NEPHRITIS: DATA FROM A POPULATION OF 67 PATIENTS WITH BIOPSY PROVEN LUPUS NEPHRITIS
MO215DEPRESSIVE DISORDER IN LUPIC PATIENTS WITH LUPUS NEPHRITIS: DATA FROM A POPULATION OF 67 PATIENTS WITH BIOPSY PROVEN LUPUS NEPHRITIS
Abstract
Background and Aims
Systemic lupus erythematosus is a multi-organ, multi-systemic autoimmune disease with significant b...
Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review
Cardiovascular Manifestations and Therapy Options for Systemic Lupus Erythematosus: A Systemic Literature Review
Systemic lupus erythematosus (SLE) is an autoimmunemulti-systemic disease; it is a controlled disease but isnot curable. SLE affects different systems in the body,such as cardiac, ...
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
SYSTEMIC LUPUS ERYTHEMATOSUS: UPDATE ΟN THE DIAGNOSIS, PREVALENCE, CLINICAL MANAGEMENT, INFLAMMATORY MARKERS, NEW HORIZONS IN THE PATHOGENESIS, MANIFESTATIONS AND PROGRESS IN TREATMENT
Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement, generating chronic inflammation and damage of more than one organ. I...
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Objectives: Bone morphogenetic proteins (BMPs) belong to the transforming growth factor superfamily that were first discovered by Marshall Urist. There are 14 BMPs identified to da...

